Redlight Guide

Surgical scar prevention

Red light therapy for surgical scar prevention

Evidence on low-level light, LED, and laser therapy for early surgical scar minimization.

Study count

Cited evidence includes an 18-RCT network meta-analysis plus two LED scar trials, including one home-based 830 nm sham-controlled study.

Evidence grade

low

Panel relevance

partially-replicable

Bottom line

This is a better category than generic 'red light for scars': keep the article focused on early post-surgical scars and clinician-approved timing.

Consensus: Surgical scar prevention has a credible but narrow signal, especially for early supervised or protocolized use; evidence is not strong enough for broad claims about all scars.

What the studies found

  • A 2024 network meta-analysis of 18 RCTs found low-level laser therapy ranked favorably among energy-based options for surgical scar minimization.
  • A 2022 sham-controlled trial of home-based 830 nm LED treatment after thyroidectomy reported better satisfaction and scar scores without noticeable adverse events.
  • A 2021 LED red-light dose-ranging study had a negative primary endpoint, some secondary improvements, and mild transient skin reactions at high fluence.

Dosage and timing

Wavelengths830 nm
IrradianceNot settled
FluenceOne dose-ranging red LED study used very high fluence levels; do not convert casually to consumer panels.
Session timeDevice-specific; one scar RCT used a 4-week home-based course.
FrequencyVaried; one red LED study used three sessions per week.
DurationOften early after surgery, with follow-up over months.
TimingSome trials began around 1 week after surgery, but timing must follow wound closure and surgeon guidance.
Treatment areaClosed surgical scar.
Device typesLow-level laser, LED scar devices, and other energy-based dermatology devices.
NotesOpen wounds, infection, delayed healing, and surgeon restrictions override consumer protocols.
  • The most defensible timing is after the incision is closed and a clinician has cleared scar care.
  • Dose is not settled across devices; high-fluence scar protocols should not be copied from abstracts.
  • Scars should be separated by type: surgical scars, acne scars, hypertrophic scars, and keloids are not the same evidence category.

Caveats

  • Do not use light therapy over open, infected, bleeding, or poorly healing incisions without medical direction.
  • Keloid-prone patients need dermatologist guidance.
  • Silicone, sun protection, wound care, and surgical aftercare remain first-line scar management.

Cited peer-reviewed sources

meta-analysis 18 included studies Evidence: moderate; direction: positive Panel relevance: partially-replicable Wavelengths: Not reported Dose/timing: Varied across included RCTs / Started within 6 months after surgery in included studies Area: Surgical scars Device: Low-level laser and other energy-based scar devices Source

Yenyuwadee S, et al. Acta Dermato-Venereologica. 2024.

A systematic review and network meta-analysis of surgical scar interventions ranked low-level laser therapy and pulsed-dye laser among effective options for minimizing surgical scars.

Source

randomized-controlled-trial 43 participants Evidence: moderate; direction: positive Panel relevance: panel-replicable Wavelengths: 830 nm Dose/timing: Home-based course after surgery / 4 weeks, starting 1 week post-operation Area: Thyroidectomy surgical scar Device: Home-based 830 nm LED phototherapy device Source

Kim, et al. Lasers in Medical Science. 2022.

A double-blind sham-controlled trial found home-based 830 nm LED phototherapy improved several thyroidectomy scar outcomes.

Source

controlled-trial Study count not extracted Evidence: low; direction: mixed Panel relevance: partially-replicable Wavelengths: Not reported Dose/timing: 160 J/cm2 / Three times weekly / 3 weeks, starting 1 week after surgery Area: Post-surgical scars Device: LED red light scar device Source

Kurtti A, et al. Journal of Biophotonics. 2021.

A split-face dose-ranging study of LED red light after surgery had a negative primary endpoint but some dose-level scar improvements.

Source

Last reviewed: 2026-06-15